

Ninth International Primary Hyperoxaluria Workshop

New York Hilton (Murray Hill A), August 28 – 29, 2010

PROGRAM

Saturday, August 28

Session 1. Advances in the Molecular Etiology and Pathophysiology of PH.

CHAIRS. Marguerite Hatch, PhD and Jaap Groothoff, MD

8:00 – 8:05: "Welcome" **Ross Holmes, PhD** (Wake Forest University)

8:05 – 8:45: "Molecular pathology of primary hyperoxaluria" **Chris Danpure, PhD** (University College London)

8:45 – 9:10: "Calcium oxalate crystal deposition in the liver of patients with primary hyperoxaluria type I" Pia Linnert, Bodo Beck, MD, Heike Gobel and **Bernd Hoppe, MD**, (University of Cologne)

9:10 – 9:35: "Experimental induction of CaOx crystal deposition in mice" **Saeed Khan, PhD** (University of Florida)

9:35 – 9:50: "Primary Hyperoxaluria presenting as chronic renal failure and swift progression to end stage renal disease in adulthood" **Dayanand Makey**, Dae Un Kim, Thomas Tomasco, Ira Strauss, Matthew Tobin and Nabet Kasabian (Jersey Shore University)

9:50 – 10:15: "The genetic basis of primary hyperoxaluria type III" **Yaacov Frishberg, MD** (Hadassah-Hebrew University)

10:15-10:30: "Phenotype of PH type III" **Carla Monico, MD** (Mayo Clinic)

10:30 - 10:50: Refreshment Break

10:50 – 11:15 "Genotype-Phenotype Correlations in PH1" – **Carla Monico, MD** (Mayo Clinic)

11:15 – 11:40 "Genotype/Phenotype correlation in PH type I - the German results" **Bodo Beck, MD** (University of Cologne), Marcus Kemper, MD (University of Hamburg) and Bernd Hoppe, MD (University of Cologne)

11:40 – 12:05 "AGT folding, dimerization and intracellular compartmentalization - synergistic interplay between a common polymorphism and many PH1-specific mutations" **Sonia Fargue, MD** (University College London)

12:05 – 12:30: “Glycine 41 variants of alanine:glyoxylate aminotransferase: molecular analyses reveal the enzymatic defect leading to PH1” **Barbara Cellini, PhD** (University of Verona)

12:30 – 1:30: Lunch Break

Session 2. Oxalate Synthesis: Novel Treatments and Insights.

CHAIRS. Gill Rumsby, PhD and John Lieske, MD

1:30 – 1:55: "Studies of stability of alanine: glyoxylate aminotransferase" **Chandra Tucker, PhD** (Duke University)

1:55 – 2:20: "Biochemical and X-ray crystallographic analysis of human 2-keto-4-hydroxy-glutarate aldolase, a novel DHDPs-like enzyme in hydroxyproline metabolism" **Travis Riedel** (Wake Forest University)

2:20 – 2:45: “Hydroxyproline metabolism in mouse models of Primary Hyperoxaluria” **John Knight, PhD** (Wake Forest University)

2:45 – 3:10: “Oxalate-degrading activities of commercial probiotic organisms” **Steven Daniel, PhD** and Alexandra Baluka (Eastern Illinois University)

3:10 – 3:35: “Can lanthanum carbonate be used as a treatment against hyperoxaluria” **Stef Robijn**, Anja Verhulst, Benjamin Vervaet, and Patrick D’Haese, (University of Antwerp)

3:35 – 3:55: Refreshment Break

3:55 – 4:20: "Audit of the performance of a DNA sequencing service for the diagnosis of PH1" **Emma Williams, PhD** (University College London)

4:20 – 4:45: “Glyoxal is a metabolic precursor of oxalate” **Ross Holmes, PhD** (Wake Forest University)

4:45 – 5:10: “Rat strain differences in renal calcium oxalate accumulation: Implications for hyperoxaluria research” **Kenneth McMartin, PhD**, Y Li and MC McLaren (LSU Health Science Center)

Sunday, August 29 Continental Breakfast 7:00 – 8:00

Session 3. The Diagnosis and Treatment of PH.

CHAIRS. Chandra Tucker, PhD and Bernd Hoppe, MD

8:00 – 8:25: “The diagnosis and treatment of Primary Hyperoxaluria” **Dawn Milliner, MD** (Mayo Clinic)

8:25 – 8:50: “Advances in the methodology for the laboratory diagnosis of Primary Hyperoxaluria” **Gill Rumsby, PhD** (University College London Hospitals)

8:50 – 9:15: "Urinary oxalate excretion is normalized in a mouse model of Primary Hyperoxaluria following intestinal colonization with /Oxalobacter sp/." **Marguerite Hatch, PhD** (University of Florida)

9: 15 – 9:40: “Development of Oxabact™ treatment for Primary Hyperoxaluria” **Harmeet Sidhu, PhD** (Oxthera, Inc.)

9:40 – 10:10: “The role of the Oxalosis and Hyperoxaluria Foundation in disease advocacy and research” **Kim Hollander** (OHF) and **Marguerite Hatch, PhD** (OHF, Scientific Advisory Board)

10:10 – 10:30: Refreshment Break

10:30 – 10:45 “Excellent isolated renal graft survival (> 25 years) in a patient with PH 1” **Ernst Leumann, MD** (University Children’s Hospital, Zurich)

10:45 – 11:10: “The impact of stone removal on kidney function” **Dean Assimos, MD** (Wake Forest University)

11:10 – 11:35: “Recent aspects of solid organ transplantation” **Markus Kemper, MD** (University of Hamburg)

11:35 – 12:10: “The collaborative European cohort of Primary Hyperoxalurias: clinical and genetic characterization with prediction of outcome” **Christiaan van Woerden, MD, PhD** and **Jerome Harambat, MD** (AMC, Amsterdam)

12:10 – 12:30: “Insights from the International PH Registry” **Dawn Milliner, MD** (Mayo Clinic)

12:30 – 12:45: “Combined registry analysis of non-I, non-II PH” **Jerome Harambat, MD** (AMC Amsterdam)

12:45 – 2:00: Lunch Break

Featured Lecture

2:00 – 2:45: "Helper-dependent adenoviral and other approaches for cell or gene therapy for oxalosis." **Arthur Beudet, MD** (Baylor College of Medicine)

Session 4. Non-Pharmacological Approaches in the Treatment of PH

CHAIR. Chris Danpure, PhD

2:45 – 3:10: "Phenotypic correction of alanine-glyoxylate aminotransferase deficient mice, with adeno-associated virus gene transfer" **Eduardo Salido, MD** (University La Laguna)

3:10 – 3:35: "Primary cultures of Hepatocytes from PH-1 patients: A potential model system for gene/ cell therapy for PH-1" **Hari Koul, PhD** (University of Colorado)

3:35 – 4:00: "Cell-based therapies for Primary Hyperoxaluria-1" **Janata Roy-Chowdhury, MD** (Albert Einstein College of Medicine)

4:00 – 4:25: "Genetic studies on atypical Primary Hyperoxaluria" **Robert Kleita, MD, PhD** (University College London)

4:25 – 4:30: "Summation: What we have learned and what is next" **Ross Holmes, PhD** (Wake Forest University)

A meeting of the Rare Kidney Stone Consortium is scheduled from 6:00 – 8:00.